Table 3.

ThiazoLidinediones in the treatment of nonalcoholic steatohepatitis.

First author/date of publication	n	Drug	Thiazolidinedione dose/study duration	Transaminase reduction	Histology
Caldwell et al. (2001)	10	Troglitazone	400 mg for 3-6 months	Yes	Steatosis, inflammation reduced
Neuschwander-Tetri et al. (2003)	30	Rosiglitazone	4 mg bid for 48 weeks	Yes	Steatosis, inflammation reduced; zone 3 perisinusoidal fibrosis reduced
Promrat et al. (2004)	18	Pioglitazone	30 mg daily for 48 weeks	Yes	Steatosis, inflammation and fibrosis reduced
Sanyal et al. (2004)	10	Pioglitazone + vitamin E vs vitamin E alone∗∗	30 mg daily for 6 months	Yes	Steatosis, inflammation, ballooning and pericellular fibrosis significantly reduced in pioglitazone-vitamin E combination arm
Tiikkainen et al. (2004)	9∗	Rosiglitazone vs metformin	8mg daily for 16 weeks	Yes	Not done; hepatic fat reduced (assessed by magnetic resonance imaging)
Belfort et al. (2006)	26∗	Pioglitazone + hypocaloric diet vs placebo + hypocaloric diet ∗∗	45 mg daily for 6 months	Yes	Steatosis, inflammation reduced in pioglitazone group; changes in fibrosis not different from placebo
Aithal et al. (2007)	30∗	Pioglitazone + diet/exercise vs placebo + diet/exercise∗∗	30 mg daily for 12 months	Yes	Steatosis and fibrosis reduced in both groups; reduction in hepatocellu-lar injury only in pioglitazone group. End of treatment biopsies showed significant differences (reduction) between the groups in steatosis, inflammation and fibrosis.
Ratziu et al. (2008)	32∗	Rosiglitazone vs placebo∗∗	8mg daily for 48 weeks	Yes	Steatosis reduced

^∗Number of subjects enrolled in the thiazolidinedione group.

^∗∗Randomized controlled trial.